Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346009 | 0.89 | TYR (0.44) | TYRACACBGRM2DRD2DRD3 | |
| SCHEMBL12640089 | 0.83 | PIK3CD (0.41) | ACACBDRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL21241923 | 0.82 | DRD2 (0.37) | DRD2DRD3KDM4EALDH1A1APOBEC3A | |
| SCHEMBL18914245 | 0.82 | ALDH1A1 (0.39) | DRD2DRD3KDM4EALDH1A1APOBEC3A | |
| SCHEMBL18914238 | 0.79 | HTR2C (0.49) | DRD2DRD3 | |
| SCHEMBL22642931 | 0.79 | DRD2 (0.36) | DRD2DRD3KDM4EALDH1A1APOBEC3A | |
| SCHEMBL12180554 | 0.79 | ACACB (0.43) | ACACBDRD2DRD3ALDH1A1 | |
| SCHEMBL9609776 | 0.79 | ADRA2A (0.42) | GRM2ALDH1A1POLB | |
| SCHEMBL16762467 | 0.78 | SMN1; SMN2 (0.43) | TYRACACBGRM2KDM4EALDH1A1 | |
| SCHEMBL18186968 | 0.78 | ACACB (0.39) | TYRACACBGRM2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020132700-A1 | METHODS OF USING INHIBITORS OF SREBP IN COMBINATION WITH NICLOSAMIDE AND ANALOGS THEREOF | Fgh Biotech Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY | 2017-11-02 | — | — | US | disclosed |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY | 2017-11-02 | — | — | US | disclosed |
| US-9738636-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738636-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160068525-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | BMP1, BMP4, BMP2 | TYR 4418/4885ACACB 3684/4885GRM2 4391/4885 |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | BMP1, BMP4, BMP2 | TYR 4418/4885ACACB 3684/4885GRM2 4391/4885 |
| US-20160068525-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | BMP1, BMP4, BMP2 | TYR 4418/4885ACACB 3684/4885GRM2 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.